Cassady Schiller Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Cassady Schiller Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$706	Buy	+3	New	+$789	﹤0.01%	875

Other funds holding ALNY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Cassady Schiller Wealth Management's ALNY Position: Q4 2024 in Review

Cassady Schiller Wealth Management opened a new position in Alnylam Pharmaceuticals (ALNY) in Q4 2024: 3 shares worth $706. The stake represents ﹤0.01% of the portfolio and ranks #875 among its holdings.

593 funds tracked by Wall St. Rank hold ALNY as of Q4 2024.

Cassady Schiller Wealth Management held 3 shares of Alnylam Pharmaceuticals worth $706 as of Q4 2024.
Alnylam Pharmaceuticals was a new Cassady Schiller Wealth Management position in Q4 2024.
Alnylam Pharmaceuticals made up ﹤0.01% of Cassady Schiller Wealth Management's portfolio in Q4 2024, its #875 holding.
593 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2024.

Based on Cassady Schiller Wealth Management's 13F filing for Q4 2024, filed 10 Feb 2025.